文献速递肿瘤 PET/CT

应用PERCIST标准评估乳腺癌新辅助化疗疗效——日本多中心研究

Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-05-12

本研究在日本多中心纳入59例乳腺癌患者,于新辅助化疗前后行FDG-PET/CT,用PERCIST评估原发灶病理完全缓解(pCR)并分析无进展生存(PFS)影响因素。PERCIST预测pCR敏感度100%、特异度30.6%、阳性预测值41.9%、阴性预测值100%、准确率53.7%;原发灶SULpeak最佳下降阈值84.3%时敏感度77.8%、特异度77.8%、准确率77.8%。完全代谢缓解(CMR)、pCR和早期TNM分期与更长PFS显著相关。结论认为PERCIST有助于预测病理反应和预后,但FDG-PET/CT倾向低估残留肿瘤,PERCIST特异度和阳性预测值相对较低,仍需联合其他影像手段预测pCR。

要点

  • PERCIST预测pCR敏感度100%(18/18)、阴性预测值100%(11/11),但特异度30.6%(11/36)、阳性预测值41.9%(18/43)。
  • 原发灶SULpeak最佳下降84.3%时,预测pCR敏感度77.8%(14/18)、特异度77.8%(28/36)、准确率77.8%(42/54)。
  • CMR(p=0.031)、pCR(p=0.024)和早期TNM分期(p=0.033)与更长PFS显著相关。

核心结论

  • PERCIST有助于预测乳腺癌患者新辅助化疗后的病理反应和预后。
  • FDG-PET/CT倾向于低估残留肿瘤,且PERCIST特异度和阳性预测值相对较低,仍需联合其他影像手段预测pCR。

研究设计与样本

  • 日本多中心研究,59例乳腺癌患者在新辅助化疗前后、计划手术切除前接受FDG-PET/CT检查。
  • 最终评估56例患者和54个原发灶;用PERCIST评估原发灶pCR,并用log-rank法和Cox法分析临床病理因素对PFS的影响。

主要发现

  • 56例患者中CMR 45例、部分代谢缓解7例、稳定代谢疾病3例、进展性代谢疾病1例;54个原发灶中分别为43、7、3、1个。
  • 54个原发灶中18个(33.3%)达pCR;PERCIST预测pCR的敏感度100%(18/18)、特异度30.6%(11/36)、阳性预测值41.9%(18/43)、阴性预测值100%(11/11)、准确率53.7%(29/54)。
  • 原发灶SULpeak最佳下降84.3%时,预测pCR敏感度77.8%(14/18)、特异度77.8%(28/36)、阳性预测值63.6%(14/22)、阴性预测值87.5%(28/32)、准确率77.8%(42/54)。
  • 56例患者中7例(12.5%)出现复发,中位随访28.1个月(范围11.4-96.4个月)。
  • CMR(p=0.031)、pCR(p=0.024)和早期TNM分期(p=0.033)与更长PFS显著相关。

关键数值与推荐

  • PERCIST预测pCR:敏感度100%(18/18)、特异度30.6%(11/36)、阳性预测值41.9%(18/43)、阴性预测值100%(11/11)、准确率53.7%(29/54)。
  • 原发灶SULpeak最佳下降84.3%:敏感度77.8%(14/18)、特异度77.8%(28/36)、阳性预测值63.6%(14/22)、阴性预测值87.5%(28/32)、准确率77.8%(42/54)。

临床怎么用

  • 作者认为PERCIST可用于预测乳腺癌新辅助化疗后的病理反应和预后。
  • 作者指出FDG-PET/CT倾向于低估残留肿瘤,PERCIST特异度和阳性预测值相对较低,仍需联合其他影像手段预测pCR。

局限性

  • FDG-PET/CT倾向于低估残留肿瘤。
  • PERCIST特异度和阳性预测值相对较低,仍需联合其他影像手段预测pCR。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to evaluate therapeutic response to neoadjuvant chemotherapy (NAC) and predict breast cancer recurrence using Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST). MATERIALS AND METHODS: Fifty-nine breast cancer patients underwent fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) before and after NAC prior to planned surgical resection. Pathological complete response (pCR) of the primary tumor was evaluated using PERCIST, while effects of clinicopathological factors on progression-free survival (PFS) were examined using log-rank and Cox methods. RESULTS: Fifty-six patients and 54 primary tumors were evaluated. Complete metabolic response (CMR), partial metabolic response, stable metabolic disease, and progressive metabolic disease were seen in 45, 7, 3, and 1 patients, respectively, and 43, 7, 3, and 1 primary tumors, respectively. Eighteen (33.3%) of the 54 primary tumors showed pCR. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PERCIST to predict pCR were 100% (18/18), 30.6% (11/36), 41.9% (18/43), 100% (11/11), and 53.7% (29/54), respectively. An optimal percent decrease in peak standardized uptake value for a primary tumor corrected for lean body mass (SULpeak) of 84.3% was found to have a sensitivity of 77.8% (14/18), specificity of 77.8% (28/36), PPV of 63.6% (14/22), NPV of 87.5% (28/32), and accuracy of 77.8% (42/54). Seven (12.5%) of the 56 patients developed recurrent disease (median follow-up 28.1 months, range 11.4-96.4 months). CMR (p = 0.031), pCR (p = 0.024), and early TNM stage (p = 0.033) were significantly associated with longer PFS. CONCLUSION: PERCIST is useful for predicting pathological response and prognosis following NAC in breast cancer patients. However, FDG-PET/CT showed a tendency toward underestimation of the residual tumor, and relatively low specificity and PPV of PERCIST showed that a combination of other imaging modalities would still be needed to predict pCR.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kitajima K, Nakatani K, Yamaguchi K, et al. Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan. Eur J Nucl Med Mol Imaging. 2018. PMID: 29754160. doi:10.1007/s00259-018-4008-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。